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Myocarditis due to systemic lupus erythematosus 
associated with cardiogenic shock
Sohaib Tariq, Anjali Garg, Alan Gass, Wilbert S. Aronow
Systemic lupus erythematosus (SLE) is a systemic autoimmune dis-
ease, known to involve different organs including the heart. One of the 
common cardiac manifestations is pericarditis [1]. Other forms of cardiac 
involvement include coronary artery disease, arteritis and valvular dis-
ease. One of the rare presentations of systemic lupus erythematosus in-
clude myocarditis and once suspected, should be diagnosed and treated 
promptly to avoid fatal consequences [2]. We report an interesting case 
of a patient with a history of SLE presenting with cardiogenic shock from 
acute myocarditis, requiring advanced heart failure therapies. 
A 41-year-old Caucasian male with a history of SLE diagnosed 2 years 
ago on treatment with hydroxychloroquine, presented to an outside 
hospital with complains of worsening shortness of breath and fatigue 
for 1 week. On initial assessment, significant findings on examina-
tion were mild confusion, jugular venous distention, crepitant rales 
at bases of both the lungs, a  grade 3/6 holo-systolic murmur heard 
at the apex which radiated to the left axilla and cool extremities. His 
heart rate was 112 beats per minute, blood pressure 98/62 mm Hg, 
respiratory rate 29 breaths per minute, serum creatinine 1.7 mg/dl, 
aspartate transaminase (AST) 4539 U/l, alanine transaminase (ALT) 
4264 U/l, serum total bilirubin 1.5 mg/dl, international normalized ratio 
(INR) 2.8 and serum lactate 5.4 mmol/l. Inotropic support with dobuta-
mine was started. Two-dimensional echocardiography revealed severe 
biventricular failure with global hypokinesis and left ventricular ejection 
fraction of 15%. Left ventricle was dilated (6.3 cm) and an apical throm-
bus was present. Left heart catheterization demonstrated non-obstruc-
tive coronary artery disease. Right heart catheterization (RHC) on inotro-
pic support showed a low output state, and an intra-aortic balloon pump 
(IABP) was placed for mechanical circulatory support. He continued to 
be in refractory cardiogenic shock and was transferred to Westchester 
Medical Center for further therapy. On arrival to our facility, the patient 
was hemodynamically unstable requiring multiple vasopressor agents 
and IABP. He continued to have evidence of end organ malperfusion. 
The decision was made to escalate mechanical circulatory support to 
venous-arterial extracorporeal membrane oxygenation (V-A  ECMO) as 
a bridge to recovery or decision. Due to a high clinical suspicion for lupus 
myocarditis, treatment with steroids, IVIG and Rituximab, was initiated. 
Right heart catheterization on ECMO support showed a central venous 
pressure of 9 mm Hg, a pulmonary artery (PA) pressure of 27/16 mm Hg 
(mean: 20 mm Hg), a pulmonary capillary wedge pressure of 12, a PA sat-
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uration of 68%, cardiac output (Fick) of 8.5 l/min 
and a cardiac index of 3.8 l/min/m2. 
Endomyocardial biopsy showed no evidence of 
significant interstitial mononuclear cell infiltration, 
intracellular depositions or myocardial necrosis. 
Trichome stain for amyloidosis was negative. The 
serum ferritin level was normal, and the human 
immunodeficiency virus antibody was negative. 
A  complete autoimmune work-up was pursued 
including anti-double-stranded DNA antibody, an-
ti-cardiolipin antibody, anti-Sjögren’s-syndrome-re-
lated antigen antibody, anti-Smith, anti-ribonucleo-
protein antibody and lupus anticoagulant, which 
were all undetectable. Serum antinuclear antibody 
(ANA) was positive with a speckled pattern consis-
tent with systemic lupus erythematosus. 
Repeat assessment of the left ventricle function 
by two-dimensional echocardiography showed 
little improvement. End organ function including 
liver enzymes and creatinine also improved. At-
tempts were made to wean off the ECMO support 
which were unsuccessful. A heart mate II was im-
planted as a bridge to heart transplantation along 
with tricuspid valve repair. No complications were 
seen while the patient was on mechanical circu-
latory support. He survived to hospital discharge, 
and two years later underwent an orthotopic 
heart transplant without any post-operative com-
plications. 
Myocardial dysfunction in SLE is usually multi-
factorial and may result from immunological inju-
ry, ischemia, valvular disease, or coexisting prob-
lems such as hypertension. Although uncommon, 
myocarditis is a serious manifestation of SLE, with 
a clinical prevalence of about 9%. However, it has 
been shown to be present in 57% of post mortem 
analyses, suggesting a high prevalence of subclin-
ical disease [3]. Myocarditis has a  varied clinical 
manifestation and can present with dyspnea, 
non-exertional chest pain, peripheral edema, fe-
ver, orthopnea, diaphoresis, paroxysmal nocturnal 
dyspnea, nausea, vomiting, or palpitations [4].
The gold standard for confirmation of myocar-
ditis is endomyocardial biopsy. However, the focal 
nature of the disease in lupus myocarditis makes 
it less sensitive. The biopsy generally reveals 
patches of myocardial fibrosis, sparse interstitial 
mononuclear cell infiltrates, and occasional myo-
cyte necrosis with immune complex deposition, 
even in areas devoid of inflammatory changes. 
The diagnosis is often achieved clinically and with 
the use of diagnostic imaging. Echocardiography 
and cardiac magnetic resonance imaging (MRI) 
are commonly used to assess biventricular func-
tion [5]. Cardiac MRI can also detect the presence 
of necrosis or scar in myocarditis by late gadolin-
ium enhancement. Left ventricular dysfunction is 
usually  global, but can present as regional wall 
motion abnormalities, chamber dilation or diastol-
ic dysfunction [6, 7]. Part of the difficulty arising in 
diagnosis of lupus myocarditis is that none of the 
current diagnostic modalities have established 
sensitivity or specificity. Management aspects of 
the disease are also not well studied. 
Myocarditis is a rare but fatal complication of 
SLE. The relative rarity of the condition makes it 
difficult to conduct controlled trials and various 
managements have been described in isolated 
case reports. High-dose corticosteroid treatment 
is the most common therapy used for lupus 
myocarditis [8, 9]. It appears to be an effective 
initial treatment resulting in improvement of 
left ventricular function in hemodynamically sta-
ble patient but there are very few cases of lupus 
myocarditis presenting as cardiogenic shock re-
quiring mechanical support. Other drugs used in 
treatment are azathioprine, cyclophosphamide, 
rituximab and intravenous immunoglobulins. Our 
patient was treated with intravenous immuno-
globulins, rituximab and glucocorticoids, which 
resulted in little improvement of the left ventri-
cle function. After undergoing orthotopic heart 
transplantation, our patient showed no evidence 
of recurrence of lupus myocarditis on subsequent 
endomyocardial biopsies and imaging during 
a follow-up of 24 months. The risk of recurrence 
of lupus myocarditis in the transplanted heart has 
not been established. 
In conclusion, lupus myocarditis can present 
as a life threatening complication. Its diagnosis is 
primarily based on clinical suspicion as diagnostic 
tools are not sensitive. Treatment is still not well 
established. We describe a case of lupus myocar-
ditis complicated by cardiogenic shock requiring 
mechanical circulatory support. 
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